Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
Status:
Active, not recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo
in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who
have suboptimal glycaemic control after conventional lifestyle or metformin intervention.